M

Mural Oncology PLC
NASDAQ:MURA

Watchlist Manager
Mural Oncology PLC
NASDAQ:MURA
Watchlist
Price: 2.04 USD Market Closed
Market Cap: 35.4m USD

Mural Oncology PLC
Total Other Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Mural Oncology PLC
Total Other Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Other Income CAGR 3Y CAGR 5Y CAGR 10Y
M
Mural Oncology PLC
NASDAQ:MURA
Total Other Income
$9.7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Alkermes Plc
NASDAQ:ALKS
Total Other Income
$2.5m
CAGR 3-Years
N/A
CAGR 5-Years
-41%
CAGR 10-Years
-4%
Amarin Corporation PLC
NASDAQ:AMRN
Total Other Income
-$377k
CAGR 3-Years
42%
CAGR 5-Years
N/A
CAGR 10-Years
-2%
Prothena Corporation PLC
NASDAQ:PRTA
Total Other Income
-$297k
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Mural Oncology PLC
Glance View

Market Cap
35.3m USD
Industry
Biotechnology

Mural Oncology PLC is a IE-based company operating in Biotechnology industry. Mural Oncology plc is a clinical-stage oncology company. The firm is leveraging its protein engineering platform to develop cytokine-based immunotherapies for the treatment of cancer. The company leverages its expertise in cytokine biology, immune cell modulation and protein engineering capabilities to develop immunotherapies. The firm is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers, particularly those with limited treatment options available. Its portfolio of programs includes Nemvaleukin alfa (Nemvaleukin)-IL-2, IL-12, and IL-18. Nemvaleukin is an engineered interleukin-2 (IL-2) variant designed to harness the potent anti-cancer capabilities of high-dose rhIL-2 while minimizing toxicity by selectively activating cancer-fighting CD8 T cells and NK cells. The tumor-targeted split IL-12 program focuses on delivering the therapeutic potential of IL-12 by splitting it into inactive component.

MURA Intrinsic Value
8.33 USD
Undervaluation 76%
Intrinsic Value
Price
M

See Also

What is Mural Oncology PLC's Total Other Income?
Total Other Income
9.7m USD

Based on the financial report for Dec 31, 2024, Mural Oncology PLC's Total Other Income amounts to 9.7m USD.

What is Mural Oncology PLC's Total Other Income growth rate?
Total Other Income CAGR 1Y
925%

Over the last year, the Total Other Income growth was 925%.

Back to Top